Shiyao Group announced that the company has previously obtained an approval notice for the phase III clinical trial of SYS6043 to treat advanced platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. This announcement announced that the randomized, multi-center, open-label phase III clinical trial evaluating SYS6043 compared to chemotherapy selected by researchers has officially launched at the first center in China, and the recruitment and screening of subjects is being actively promoted.

Shiyao Group announced that the company has previously obtained an approval notice for the phase III clinical trial of SYS6043 to treat advanced platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. This announcement announced that the randomized, multi-center, open-label phase III clinical trial evaluating SYS6043 compared to chemotherapy selected by researchers has officially launched at the first center in China, and the recruitment and screening of subjects is being actively promoted.